✦ LIBER ✦

Safety and immunogenicity of a new formulation of interferon -1a (Rebif(R) New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

✍ Scribed by Giovannoni, G; Barbarash, O; Casset-Semanaz, F; King, J; Metz, L; Pardo, G; Simsarian, J; Sorensen, P.; Stubinski, B

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND2 SAFETY AND IMMUNOGENICITY OF REBIF®

✍ J Simsarian; A AL-Sabbagh; R Bennett; B Stubinski; G Pardo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Rapid benefits of a new formulation of s

✍ De Stefano, N.; Curtin, F.; Stubinski, B.; Blevins, G.; Drulovic, J.; Issard, D. 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 183 KB

A multicenter, open-label, phase II stud

✍ J.Theodore Phillips; George Rice; Elliot Frohman; Luc Vande Gaer; Thomas Scott; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 113 KB

Rebif® Quality of Life (RebiQoL): A rand

✍ D. Bandari; D. Wynn; T. Miller; B. Singer; S. Wray; R. Bennett; B. Hayward; F. D 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 552 KB

PO10-TU-33 Development of a new formulat

✍ G. Giovannoni; N. De Stefano; M. Migliaccio 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Immunogenicity and tolerability of an in

✍ Gavin Giovannoni; Olga Barbarash; Florence Casset-Semanaz; Amer Jaber; John King 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 222 KB